Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2026

Relationship between metabolic dysfunction-associated steatotic liver disease and cardiovascular mortality risk in individuals with CKM stages 0-2: Mediating roles of inflammation and insulin resistance.

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZhuoxing LiQYQianyu YangLZLi Zang

Discussion

Loading...

Member takes

Overview

Randomized trial examines CVD mortality risk linked to MASLD in early CKM stages, suggesting clinical implications.

Key Points

  • The aim is to explore the link between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular mortality in individuals with CKM syndrome stages 0-2.
  • Analyzed NHANES data from 2009-2018 including 10,061 adults with CKM syndrome, focusing on those in stages 0-2.
  • Utilized statistical models including restricted cubic spline models, Kaplan-Meier analysis, and multivariable Cox regression.
  • Conducted mediation analyses to examine insulin resistance and inflammation as mediators in the observed relationship.
  • MASLD prevalence increased with progression of CKM stages.
  • In CKM stages 0-2, USFLI scores showed a significant linear correlation with cardiovascular mortality risk (P < 0.001).
  • Participants with MASLD had a higher hazard of CVD mortality (HR = 4.03, 95% CI 1.55-10.48) compared to those without.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a55d1475aafca87247f8541https://doi.org/10.1016/j.diabres.2026.113411
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Stratified Burden of MASLD in Cardiovascular-Kidney-Metabolic syndrome: Stage-Dependent Prevalence and Insulin Resistance-Driven Cardiovascular Mortality2025 · 1 citations
  2. 2Abstract MPTH69: Metabolic Dysfunction-Associated Steatotic Liver Disease Across the Cardiovascular-Kidney-Metabolic Spectrum: Insights from the CARDIA Study2026
  3. 3Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD2025 · 22 citations
  4. 4Population‐Based Study on the Coexistence of Metabolic Dysfunction‐Associated Steatotic Liver Disease and Chronic Kidney Disease2025 · 20 citations
  5. 5Screening for Chronic Renal Insufficiency Should Focus on People with Diabetes, Insulin Resistance or Advanced Fibrosis in MASLD2024